Baird Capital buys stake in Prescient

The stake was acquired for £15.5m, although the percentage remains undisclosed.

Prescient's board of directors will include Baird Capital's Andrew Ferguson and John DiGiovanni. Baird was first introduced to Prescient three months before the deal took place, having been on the lookout for investments in the pharmaceutical space. The GP sold its previous investment in the industry in 2006. 

The deal is the third investment to be made from the GP's Global Fund, which raised $310m as of June 2017. It acquired a majority stake in aircraft components company CAV in June 2017 and bought a majority stake in US digital marketing agency R2Integrated in September 2016, ahead of the fund closing.

The fund's strategy is to invest in 10-15 companies targeting the UK, US and China, partner Andrew Ferguson told unquote". It invests along two broad sector lines: industrial and manufacturing solutions, and technology and services.

Company
Founded in 2007, Prescient is headquartered in London with offices in the US, India and China. It is a provider of product strategy services to assist clients in making clinical and commercial decisions.

People
Baird Capital – Andrew Ferguson (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• Baird Capital Partners Europe Ltd
• United Kingdom